Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Bayer's Lynkuet Receives FDA Approval for Treating Menopausal Hot Flashes

Bayer's Lynkuet Receives FDA Approval for Treating Menopausal Hot Flashes

The U.S. Food and Drug Administration (FDA) has granted approval to Bayer's novel oral therapy, elinzanetant, for the treatment of moderate to severe hot flashes in menopausal women. The drug, to be marketed under the brand name Lynkuet, represents a significant advancement in menopause management as the first FDA-approved therapy that targets both neurokinin 1 and neurokinin 3 receptors to alleviate vasomotor symptoms (VMS).

NoahAI News10/27/2025
Organon CEO Resigns Amid Improper Sales Practices Investigation

Organon CEO Resigns Amid Improper Sales Practices Investigation

Organon, a prominent women's health company, is facing a significant leadership shakeup following an internal investigation that uncovered questionable sales tactics for its birth control implant, Nexplanon. The probe has led to the resignation of CEO Kevin Ali and the termination of the company's head of U.S. commercial and government affairs.

NoahAI News10/27/2025
Robotic Heart Valve Surgery: A New Frontier in Minimally Invasive Cardiac Care

Robotic Heart Valve Surgery: A New Frontier in Minimally Invasive Cardiac Care

Corcym and CardioPrecision have joined forces to develop a groundbreaking robotic approach to aortic valve replacement, potentially offering patients the benefits of both minimally invasive procedures and traditional open-heart surgery. This collaboration marks a significant advancement in cardiac care, combining innovative technologies to improve patient outcomes and recovery times.

NoahAI News10/27/2025
Zenas Biopharma's MS Drug Shows Promising Results in Phase 2 Trial

Zenas Biopharma's MS Drug Shows Promising Results in Phase 2 Trial

Zenas Biopharma has reported encouraging results from a phase 2 clinical trial of its lead autoimmune drug, obexelimab, in patients with relapsing multiple sclerosis (MS). The study, known as MoonStone, demonstrated a significant reduction in brain lesions, a key marker of MS disease progression.

NoahAI News10/27/2025
Machinify Expands AI-Powered Healthcare Payment Integrity with $670M Acquisition of Performant Healthcare

Machinify Expands AI-Powered Healthcare Payment Integrity with $670M Acquisition of Performant Healthcare

Machinify, a leading healthcare data company, has completed its acquisition of Performant Healthcare for approximately $670 million, marking a significant expansion of its artificial intelligence-driven payment integrity platform. The deal, which closed recently, is set to broaden Machinify's reach into government programs and enhance its ability to serve both commercial and government payers.

NoahAI News10/27/2025
BridgeBio's Limb-Girdle Drug Shows Promise in Late-Stage Study

BridgeBio's Limb-Girdle Drug Shows Promise in Late-Stage Study

BridgeBio Pharma has announced positive results from a late-stage study of its experimental medicine, BBP-418, for a form of limb-girdle muscular dystrophy. The success of this trial positions the company to engage with U.S. regulators about a potential approval filing, marking a significant step forward in addressing an unmet medical need.

NoahAI News10/27/2025
Hemab Therapeutics Secures $157M Series C Funding to Advance Rare Bleeding Disorder Treatments

Hemab Therapeutics Secures $157M Series C Funding to Advance Rare Bleeding Disorder Treatments

Hemab Therapeutics, a biotech company focused on developing treatments for rare bleeding disorders, has successfully raised $157 million in a Series C funding round. The oversubscribed financing, led by Sofinnova Partners, positions Hemab to accelerate its ambitious pipeline and advance clinical candidates for underserved conditions such as Glanzmann thrombasthenia and von Willebrand disease.

NoahAI News10/27/2025
MapLight Therapeutics Goes Public with $250M IPO to Fund Schizophrenia Drug Development

MapLight Therapeutics Goes Public with $250M IPO to Fund Schizophrenia Drug Development

MapLight Therapeutics, a California-based biotech company, has successfully launched its initial public offering (IPO) on the Nasdaq, raising $250 million to advance its pipeline of central nervous system (CNS) therapeutics. The company's flagship program aims to challenge Bristol Myers Squibb's schizophrenia medication, Cobenfy, in an increasingly competitive market for novel CNS treatments.

NoahAI News10/27/2025
BridgeBio's Phase 3 Success Paves Way for FDA Filing in Rare Muscular Dystrophy

BridgeBio's Phase 3 Success Paves Way for FDA Filing in Rare Muscular Dystrophy

BridgeBio Pharma has announced groundbreaking results from its phase 3 trial for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study's success has positioned the company to pursue FDA approval, potentially bringing a new therapy to patients with this rare genetic disorder.

NoahAI News10/27/2025
GSK Expands ADC Portfolio with $357M Syndivia Deal for Prostate Cancer Prospect

GSK Expands ADC Portfolio with $357M Syndivia Deal for Prostate Cancer Prospect

In a significant move to bolster its oncology pipeline, GlaxoSmithKline (GSK) has entered into a lucrative partnership with French biotech Syndivia. The collaboration, announced on October 27, 2025, centers around a preclinical antibody-drug conjugate (ADC) targeting metastatic castration-resistant prostate cancer (mCRPC).

NoahAI News10/27/2025
Coya Therapeutics' Daniel Barvin: A Personal Mission to Combat Genetic ALS and FTD

Coya Therapeutics' Daniel Barvin: A Personal Mission to Combat Genetic ALS and FTD

Daniel Barvin, VP of Operations and Patient Advocacy at Coya Therapeutics and a carrier of the C9orf72 mutation, is leading a charge against amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). His journey from wealth management to biotech exemplifies a growing trend of personal investment in the pharmaceutical industry's fight against neurodegenerative diseases.

NoahAI News10/27/2025
Breakthrough in Huntington's Disease Treatment Sparks New Wave of Therapies

Breakthrough in Huntington's Disease Treatment Sparks New Wave of Therapies

In a groundbreaking development for the Huntington's disease (HD) community, recent clinical trial results have reignited hope for effective treatments. This surge of progress comes after years of setbacks, with several pharmaceutical companies now racing to bring disease-modifying therapies to market.

NoahAI News10/27/2025
«1...212223...67»